NCT00831792View on ClinicalTrials.gov

TKI258 in Castrate Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 7, 2010

Primary Completion Date

June 12, 2017

Study Completion Date

June 12, 2017

Conditions
Prostate Cancer
Interventions
DRUG

TK1258

4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER